C-VIMYBottneuro
personalized tES, EEG, 3D-printed neurostimulation
diagnosticsdevice hardware
Loading
Loading section...0-100 chain-logic scale · 15 dimensions · scored on public evidence
←All companiesC-VIMY
C-VIMYC-VIMYpersonalized tES, EEG, 3D-printed neurostimulation
0-100 chain-logic scale · 15 dimensions · scored on public evidence
The present study aims to assess the safety and feasibility of repeated transcranial alternating current stimulation (tACS) by the Miamind Neurostimulator in a cohort of healthy participants. Based on the findings of this investigation, subsequent clinical trials assessing the efficiency of tACS by the Miamind Neurostimulator for treatment of Alzheimer's Disease will be conducted.
Venture Kick - 1 Million Plus to kick your startup to success Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY --> Login Username Password Forgot password / Create a new password EN DE FR Login Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY EN DE FR Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY Login VENTURE KICK IN THE NEWS 25.06.2026 Nanoflex Robotics awarded EUR 12.5 Million from the EIC Accelerator 24.06.2026 Perovskia Solar wins EUR 2.25M EIC Accelerator Grant 23.06.2026 Omics-OS receives CHF 40,000 f … ick to redefine power electronics 17.06.2026 BTRY wins EUR 2.2M EIC Accelerator grant 16.06.2026 Monarch Technologies receives CHF 40,000 from Venture Kick to accelerate validation toward clinical translation 16.06.2026 SonoStent receives CHF 40,000 from Venture Kick to advance non-invasive urinary stent technology 15.06.2026 Immitra Bio receives CHF 150,000 from Venture Kick to reimagine stem cell therapy for rare diseases 15.06.2026 PolaSight receives CHF 40,000 from Ventur … ries 11.02.2026 Two Venture Kick alumni reach final round of the Green Business Award 2026 09.02.2026 Chiral raises USD 12M to scale post-silicon computing beyond Moore's Law 03.02.2026 Haelixa secures EUR 2 million to boost global growth 02.02.2026 Sun-Ways and SNCF Group team up to test solar panels between railway rails 02.02.2026 DiploTools receives CHF 150,000 from Venture Kick to build purpose-built AI tools for modern diplomacy 29.01.2026 CHF 1.25 Billion Invested in V … ps merger creates USD 1B employee experience platform 01.07.2025 Migros Pioneer Fund: Supporting impact innovation 01.07.2025 Adiposs Raises CHF 4M to advance cancer imaging tool 01.07.2025 RTDT secures USD 4 Million in Pre-Seed Round to scale wind energy platform 26.06.2025 CHF 40,000 for an AI-Powered insurance platform, a risk analysis co-pilot software, and an AI-powered virtual fitting room 24.06.2025 CHF 40,000 for simple aerial transportation, recyclable electronics, a … biomaterials 16.05.2025 Eight Venture Kick alumni among finalists for De Vigier Award 2025 15.05.2025 CHF 40,000 for autonomous drones for extreme environments, next-gen DNA-encoded libraries, and a vaccine to reduce the antibiotic need. 12.05.2025 CHF 10,000 for a scientific collaboration platform, a compact tabletop high-throughput screening de
Meet Our Team of Professionals | Lexington Medical, Inc. Skip to content Products AEON™ Powered AEON™ Clinical Resources Blogs Surgical Specialties Thoracic Surgery HPB Surgery Bariatric Surgery Colorectal Surgery Urologic Surgery General Surgery Publications Company About Leadership Careers Our Culture Career Opportunities Internships & Co-Ops Contact Contact Us Request a Demo Products AEON™ Powered AEON™ Clinical Resources Blogs Surgical Specialties Thoracic Surgery HPB Surgery Bariatric Surgery Colorectal Surgery Urologic Surgery General Surgery Publications Company About Leadership Ca
#swissstartups #swisstech #venturecapital | Gianmaria Sbetta | 13 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreem
Five startups from the Basel Area feature in the TOP 100 Swiss Startup Award - Basel Area Business & Innovation Skip to main content How we help Open Sub Menu Land Helping global companies locate in the region Launch Helping startups and scaleups get off the ground Level up Helping established businesses unlock new growth Our programs Why the Basel Area Insights Events Who we are Open Sub Menu Meet our team Partners Media enquiries Careers Contact us EN EN DE Go to search page Contact us Home / Insights Five startups from the Basel Area feature in the TOP 100 Swiss Startup Award The 14th e … n the TOP 100 Swiss Startup Award The 14th edition of the TOP 100 Swiss Startup Award has named the greatest startups in Switzerland. Five startups from the Basel Area are represented in the TOP 100 ranking. --> News September 5, 2024 6 min read Five startups in the TOP 100 ranking come from the Basel Area, a flourishing region for startups in the fields of biotech, medtech, and healthtech. The biotech startup FimmCyte from the portfolio of the accelerator and incubator BaseL
Venture Partnerships & Investments | Zühlke Skip to main content Zühlke - zur Startseite Business Careers Events About us Language navigation. The current language is english Impact Sustainability Diversity, Equity & Inclusion Code of conduct Modern Slavery Statement Looking for your next opportunity? Explore all our open vacancies here! Discover our Jobs Leadership Partnerships AWS Microsoft Mendix Subscribe to receive the latest news, event invitations & more! Sign up here Ventures News Zühlke - zur Startseite Business Careers Events About us Impact Sustainability Diversity, Equi … gital Biomarkers are currently applied in multiple sclerosis and have potential application in many diseases in neuroscience as well as rare diseases. Learn more Learn more Koya Active compression treatment for lymphedema patients allowing for more flexible and portable treatment at home or on the go. Learn more Learn more Noctrix Health – Neuromodulation Therapy A wearable neuromodulation therapy for treating sleep disorders; initial focus is Restless Legs Syndrome (RLS). Th … policy Cookie policy Legal notice Modern slavery statement Imprint Request for proposal We appreciate your interest in working with us. Please send us your request for proposal and we will contact you shortly. Request for proposal © 2026 Zühlke Engineering AG Follow us External Link to Zühlke LinkedIn Page External Link to Zühlke Facebook Page External Link to Zühlke Instagram Page External Link to Zühlke YouTube Page Language navigation. The current language is english
C-Level managers for tech startups News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capital Report Download the latest re … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout C-Level managers for tech startups Expansion Please login or register 09.05.2022 The startups Starmind, Bottneuro, GlycocEra and PriceHubble have attracted seasoned managers to their teams, assuming new roles as Chief Customer Officer, Chief Technology Officer, and Chief Executive Officer. Proptech startup PriceHubble has won a leading UK banker as an advisor and invest … to use the awards follow feature Highlights Bottneuro AG Top 100 Swiss Startup Award 2024 Winner Venture Kick Highlights GlycoEra AG Top 100 Swiss Startup Award 2022 Top 100 Swiss Startup Award 2023 Top 100 Swiss Startup Award 2024 Top 100 Swiss Startup Award 2025 Highlights PriceHubble AG Top 100 Swiss Startup Award 2018 Top 100 Swiss Startup Award 2019 Top 100 Swiss Startup Award 2020 Top 100 Swiss Startup Award 2021 Highlights Starmind International AG Top 100 Swiss Start … s Startup Award 2021 Highlights Starmind International AG Top 100 Swiss Startup Award 2014 Top 100 Swiss Startup Award 2015 Related tags Read more about People Principal Investments 2026 The Swiss Venture Capital Report 2026 offers key insights into the latest trends shaping the investment landscape. Download the report in our assets section . Us
US20120245653A1 - Neurocranial electrostimulation models, systems, devices and methods - Google Patents US20120245653A1 - Neurocranial electrostimulation models, systems, devices and methods - Google Patents Neurocranial electrostimulation models, systems, devices and methods Download PDF Info Publication number US20120245653A1 US20120245653A1 US13/264,142 US201013264142A US2012245653A1 US 20120245653 A1 US20120245653 A1 US 20120245653A1 US 201013264142 A US201013264142 A US 201013264142A US 2012245653 A1 US2012245653 A1 US 2012245653A1 Authority US United States Prior art keywords tissue elec … and makes no representation as to the accuracy of the status listed.) Abandoned Application number US13/264,142 Inventor Marom Bikson Abhishek Datta Lucas C. Parra Jacek Dmochowski Yuzhuo Su Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.) Research Foundation of City University of New York Original Assignee Research Foundation of City University of New Y … sted.) 2009-04-13 Filing date 2010-04-13 Publication date 2012-09-27 2010-04-13 Application filed by Research Foundation of City University of New York filed Critical Research Foundation of City University of New York 2010-04-13 Priority to US13/264,142 priority Critical patent/US20120245653A1/en 2011-11-11 Priority to US13/294,994 priority patent/US8494627B2/en 2012-06-01 Assigned to RESEARCH FOUNDATION OF THE CITY UNIVERSITY OF NEW YORK reassignment RESEARCH FOUNDATION OF T … ; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS G16H — HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA G16H50/00 — ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics G16H50/50 — ICT s … ; INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS G16H — HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA G16H30/00 — ICT specially adapted for the handling or processing of medical
%PDF-1.3 %��������� 3 0 obj > stream xm�;O�0���SB�����n�5���Sr��?v��(�^���ٽ� �c��j�3(.k ��Ru�d�yX��e������>b��m�`j5P]tא����'t��x����B� ��gì�vK_Q#֯�k�[D�� )jh���V�>����C��ƖB�w�G9ੴ~QG6 endstream endobj 1 0 obj > endobj 4 0 obj > /Font > /XObject > >> endobj 5 0 obj > stream x��iw�5��� �6��' $h�Ј�$$1������#�[ �>��]+W���ꪬ��ȽcGF����z�����מ������͟�^����gW|�T�硵��o �|���ݳ N�� ��}|�Ή��S�w�\yp~����'�ˏ�-? ]{va����gC��� f��gv��� k�ϯ>�߿�9���囿�l�|�����? ���������'g�O��q!����C ]hl��南Sۯ�>��������x���ÿ��C�☵{��o�Yz|l���;�����Ss�N�� ������/��>���؍×n��� Y~2��ʅ����v����ϳ7>\\{u~�� … ��+����e`��'�J�#D�bd�&c�ī�ˈ�K�2��\ �����i�'�6�����x ѐ&B~�@[�2�u���*����RFp�����K �J+ܽ�2�L�OF.�����Q���ʨ}�\�j�R?��ʂ/��+j%ܞ�En,�����5`�� B/�.�x8NL�Q���x�mN{����r����Ü��|9@����a�N8�+8�`"���}���4�\ ��!� ��z���تﾍ�NXϷ��� ��b��k�S�ҪR�AB;�ʷ�K�[ԃO�9��.442� � I�٥�h@��Y%���R�'���v! �p�'��R`B� � �Z���aԀoPv������8�spI���[J��H�c-,���]ޮ�;��7�K�-pB/r��W�Fb$Pc���_��x��`��7��p4��63y�BW�!��lҊ� �T��(2����^3��?2��O[D6����T��\���䶐����)3���� ��� �,(� … 9=�eH=��Չ�\2�p5����n��m��� �i����d�Y�v-w�;Cnt���fч- �= IgNW'{�#�l��2z���rfp/� �����;p\�RhV�˻Lб=� F� ����3 ��Ic&P6>��I�1����;�.R~ �7do@�ú�@.E�f}i!�� Ѕ����xi>1�d+a��l�m@ ���/!%�D�9j�j�k�7z��)�E����yKCd����2���-�+܂��OHt�=��L�y9W7O����ut [�Q�Ӎ����9H:�գ�_���*�^����J ���jGA���� �O�, C�Q"t`Jߦ���8#���� �Smy\Go˄*��x� gB�-.��Iu0�ۇ�*)E����o�|����`K睒z*'L�z��J��B�[��oMcs�$;l�����[*$#gy4H�����������% ������5q ��r���rxΚ@p����iU-x�5��� �=Ki�� … ���(��.���+E;cLb��_����]V۶��h�D�u6�%z *�p�ؾ#X~A�¢v �� �/떬��g��V�=�����*����rFp�y�%�12$K�g,�;�ͱoi�\�aV�� �Z�b���nrZԩ���L�B J�M�wt�?A�`JJS@�y������/{�Om����ost`�w�ܖzq����O��%g�5�fD��zTH�'��~�j��\����AxY�-���OC��GU��� sK>��нq�;�r\�% ��$�z4m �����\�}q�S���퍞o��� כv{�_Z� ��l�,F-� X�8�9�̚0���ᨢ@)f&|c4LsIs�f�s�r�} CjY� 6ZBS������G��!���������, �嘼�����N_�p �f@��Y��s��X�����X9��.�̓�w 1^>q>~I^~Q&Y~EA�%�ҋEedѡ&�чB�H ������-[�z��������Z��s�Г�
Patient Statement | Bottneuro AG LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , and Cookie Policy .
%PDF-1.7 %���� 1 0 obj >/Metadata 2526 0 R/ViewerPreferences 2527 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/Font >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595 842] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��][�中~o��C=Nh�A]5Ӄ �@�� A �I#@vr���G�%Y7��2]����*)��>R$}z��Ӈ|��D��N珗���?������uǩ �Is5hu�l�����?����� u�v7_&����즟~��{���_^�����~ww����tJSO��#��G����I�F�Z� ͯ��e� �zG Yj(�AqCr ��Đ$�W���?Ln$�����O�N>�����O�WZ��h6&͋ X��F� �>5s������-r ���˷�ӻ�� ����[�a':f�P!"Oj s����*�ky��-N�00r|;��> ��$�iuPz�ګE�tk
%PDF-1.7 %���� 1 0 obj >/Metadata 20318 0 R/ViewerPreferences 20319 0 R>> endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj >/Font >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 960 540] /Contents 5 0 R/Group >/Tabs/S/StructParents 0>> endobj 5 0 obj > stream x��Y�n�}'��Ǚ8��ea�l٫�N K�E�̓BS���J�&��T��ɱd���/é��T�:]]ݜ?��9;9^�T{o�W�M'�R�RJ�b����S��r:��j5��_ �����Q/� ����3��� ��V�oLp��t��ڧ�7>;�1ShgM=b��Y�RWڷ�WG'Ӊ�~�ҕխ� �p �3��ի�� ��ffb��hS�mf��k3sEy���:��t���v���H�ɷcf���wV W&S[ t��L���Z�T'�S��V'��)Χ��ϡF&� P��Άd� �A�!�u�����i�[�+� �md��G����L[�fKA#+�:\%Jo( �>n … CI%�Y��\�M�i MX7,�K�g�gc^} �eH9�k7�P��jĒn �I�pj�g'q�!c��b�pin@Ȩ�e�U�rFp)`�\��� 7���b����9�I�;h[��0�s�I���8ǽC �=)�[;w T�D����pj7` 8�nV'nx�����G�{�ΦpFݪG�G s���S��x�� ���E5��`x��u�Њ�8��Q�q ��F �2F'�O&1�w �r��z RZ�cBL���1O(�=�c �������3����Ϛ"9# �iXN�W�勂���{s �� ���t�Yk�E�!�!h��9�~>���Fdf{�$I?�z� )��+���3,��%�&����N��)sǙt5�+'��nt���2�h���`?�b��3Mv�%��a�^��� ��Bu��Q�d����?QY��� �l.ѣ��U�N)��d�#�� ���g U�p �Z��.��&[����W;.��XI��)c[pr�x�
Ambitious partnerships News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capital Report Download the latest reports SVCR-D … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout July 25, 2025 Ambitious partnerships Dear reader Aldi Switzerland, in collaboration with the foodtech start-up Planetary , has rolled out a plant-based, mycoprotein chicken fillet across all its stores in Switzerland, marketed under the MyVay brand. This milestone is built on Planetary’s strategic acquisition of Libre Foods and marks the company’s first B2B launch. Swis … awards, camps and accelerator programmes are fast approaching: Future of Health Grant closes registration on 31 July, Vesalius Innovation Award on 2 August, Swiss Technology Award on 8 August and the Biopôle Investment Programme on 12 August. An overview can be found in our calendar . Have a good weekend. Ritah Nyakato Baldegger Duty Editor, Startupticker.ch News 25.07.2025 15:05 $6.5 million to accelerate the future of domain names and digital Identity Freename, the startup … n sind jeweils einige Startups unter den Finalisten. Wer dann einen Real Estate Award, eine Auszeichnung als Rising Star der Gastro- und Hospitality-Branche oder ein Förderpaket von Helbling mit nach Hause nehmen kann, entscheidet sich zwischen September und November. Tags: Call to Action, Swiss start-up environment 23.07.2025 11:00 4 Millionen F
All blocks - Switzerland Innovation Park Basel Area menu search search close back Home Workspaces Community Sites About Us Latest & Events Contact Workspace offerings Coworking spaces Lab spaces Customizable spaces Ready-made office spaces Ready-made workspaces overview Private offices Lab spaces Coworking spaces Customizable spaces Meeting rooms Community Residents Alumni Success stories Main Campus Novartis Campus Jura About us Team Jobs Media corner Latest Events Contact Become A Resident Main Campus Main Campus HQ HORTUS ALL EVENTS THE MAGNET Become A Resident Login You're leaving our webs … all articles with dilers and pagination. Filter by All Blog News Success Story Apply Filter Blog Before you sign: a biotech founder’s guide to renting lab space in the Basel Area What biotech founders should check before renting lab space in the Basel Area – from hidden costs and compliance to flexibility, IP and speed to first experiment. Read More Success Story A new deep tech success story takes shape in the Jura: Inveel The Switzerland Innovation Park Basel Area – … 9, the area will consist of five buildings, constructed by SENN and designed by award-winning architects. Learn more Novartis Campus Located in the city of Basel, the Switzerland Innovation Park Basel Area – Novartis Campus is the only coworking space on the Novartis Campus. It offers a range of shared workspaces, private offices and innovation areas tailored to the needs of startups, entrepreneurs and innovators in the field of digital health and health tech. Our modern faci … nd cellular targeting. Versameb’s proprietary technology platform optimizes the application of functional mRNA in different disease contexts. The company is based in Basel, Switzerland and is fully operating since 2018. Details Volv Global SA Volv help to diagnose patients with difficult to diagnose or rare diseases with our inTrigue product. Details Worg pharmaceuticals Worg Pharmaceuticals (Hangzhou) Co., Ltd. is a clinical stage biopharmaceutical company developing new tre
Bottneuro: Enabling Patients to Improve Health with Neurocognitive Disorders Device | Switzerland Innovation Park Basel Area posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join Link
Elektrotherapiegeräte Skip to main content Main navigation Close Back --> --> --> Home Help & Arrival Contact International Representatives Arrival Hotel & CityInfos FAQ Exhibit Trade Fair Participation Online registration Become an exhibitor Stand Cost Calculator Trade fair preparations Information Contact persons Download center At a glance Service ABC Hotel & CityInfos Stand constructor portal Traffic regulations Services Fair Match Online-Order-System (OOS) Exhibitor Profile Exhibitor dashboard Scan2Lead Logos & banners Trade fair presence Stand construction services Marketing Press Servic … Press Accreditation Press contact Press releases Exhibit Exhibit Exhibit Online Application Online Order System Marketing Services Exhibitor contact Dashboard Parallel event Parallel event Parallel event MEDICA About COMPAMED About COMPAMED About COMPAMED Product Categories At a glance Newsletter Spheres of COMPAMED-Magazine Contact & Support Write to us Hotline +49 211 /4560-01 FAQs Digital Services Act (DSA) Legal Imprint Privacy Policy Accessibility Compliance Cookie Setti
%PDF-1.6 %���� 11434 0 obj > endobj 11462 0 obj >/Filter/FlateDecode/ID[ ]/Index[11434 56]/Info 11433 0 R/Length 125/Prev 18548637/Root 11435 0 R/Size 11490/Type/XRef/W[1 3 1]>>stream h�bbd```b``["�@$�-Xd7�������� 0�& �d��&MA$w �� "���f��Hfn�V��̎���jvI�~k0�,ޅp� ���7����A�$t��k�� �f� endstream endobj startxref 0 %%EOF 11489 0 obj >stream h��T�Oe��+l��젵P���[���/�3�c@&��� �F�X:u �*���(s�-��[�� �ˌKZ� ���R(L�`f��9u.�����x����y>��{�{@ �)�� @ �]qbܕ� ����@���� R,u�sIܔx7:v�N�ő�`�X��b!� _UK{�8Z�4w� �p/������k��n��� �i�l�&�k?�i�a�RJ&�oԴ�'K��+?��xî������> … �҅=�~i��SK�͑�~������ZzL��,>o�� Y�_sy�@ endstream endobj 11456 0 obj >stream application/pdf Gelb_80_TRY_TOP100_Platform Adobe Illustrator 26.5 (Macintosh) 2024-07-26T09:37:51+02:00 2024-07-26T09:37:51+02:00 2024-07-26T09:37:51+02:00 proof:pdf uuid:65E6390686CF11DBA6E2D887CEACB407 xmp.did:db9b1d68-119d-40aa-ad76-2caeaa44ea40 uuid:05bede8e-a280-6a4e-b41e-81525614f74a uuid:82404809-d6f2-8c42-ae52-87e0d3fccdb9 xmp.did:f3ae50e6-3ddd-42a7-b237-a4ca1bdb4783 uuid:65E6390686CF11DB … 018-07-13T11:19:34+02:00 Adobe Illustrator CC 22.1 (Macintosh) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:6554a403-57d2-1445-9885-d3879b79ed0a 2019-04-15T14:10:46+02:00 Adobe Illustrator CC 22.1 (Windows) / converted from application/postscript to application/vnd.adobe.illustrator converted from application/postscript to application/vnd.adobe.illustrator … ?��Q.�+O�c3WD;�Px���^VSM��ֻ ^6�W��t]Cr2��I�f��/P���ٔ�B� `-=[|}����L x rfP`w[Hn���r�u���(�I@�%L�X� ��j�U����{�쥩Q� ���8�w$��[,b��1F�Po���h�} �9�g�����o��~~1 �B�Z���l�l�Bw4�ޱ(� �q B0��)3��� �xM.5D��Ǩ�\���Nw�Lx4�f+�V�Z�� ��I3� ��[�����ׅlHv@�^z��c!� >z �o]p>�&�ڂS��J� '����J@�%��)�؎�Re�r ^�� ���q�m���79��� �3X�qg��*T���{�ܶ�~#�Q"LB&>~ ��~ d�r�:mZ-7Q��m�R�Y�g+��od�4����3�_;�E{ ]��E�Z~�sBx7�vR�):��~}�/$�~���|}.�T�'�#2�?�-� � "C ��P���`��" … 6T16:43:21+02:00 OneVision PDFengine (Linux 64bit Build 46.029.S) False PDF/X-4 application/pdf 42689_Inserat Growth Advisory New_210x282_2024-07-26-EN.indd uuid:5e5f9c28-bd3e-8946-a509-4e2871e24ddb xmp.did:9725d04b-ce4d-41d6-92c4-c9985f462f4a default uuid:66a789b9-0000-1000-8567-d0169b3ebd4b 1 xmp.did:9725d04b-ce4d-41d6-92c4-c9985f462f4a xmp.did
Bottneuro Launches Miamind.ch - Miamind Skip to content Home Miamind Science News Contact Home Miamind Science News Contact How to get Miamind? EN DE Get in touch EN DE Home Miamind Science News Contact Home Miamind Science News Contact Bottneuro Launches Miamind.ch Posted on 28 April, 2025 Bottneuro AG proudly announces the launch of miamind.ch , the official webpage for the Miamind® Neurostimulator. This custom-made, non-invasive brain stimulation device is designed to provide personalised therapy for neurological conditions such as Alzheimer’s disease. The newly launched website offers comp
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
%PDF-1.5 %���� 3623 0 obj > endobj xref 3623 323 0000000016 00000 n 0000018230 00000 n 0000018382 00000 n 0000018420 00000 n 0000020349 00000 n 0000020466 00000 n 0000020582 00000 n 0000020697 00000 n 0000020810 00000 n 0000020861 00000 n 0000020900 00000 n 0000035679 00000 n 0000049549 00000 n 0000063334 00000 n 0000077492 00000 n 0000093038 00000 n 0000109046 00000 n 0000110252 00000 n 0000111457 00000 n 0000112662 00000 n 0000114008 00000 n 0000115202 00000 n 0000116401 00000 n 0000116536 00000 n 0000116671 00000 n 0000118769 00000 n 0000118857 00000 n 0000120192 00000 n 0000122306 00000 n … > �c�?>^�i�>7`�/����a�� �_������v���۫�x���f��/��� Nڟ���9�!o�l��� � ��� >stream application/postscript Vorlagen Logo_pfade.indd Adobe Illustrator CS3 2011-09-05T11:44:54+02:00 2011-09-05T11:44:54+02:00 2011-09-05T11:44:54+02:00 uuid:6EB8AFE841D9E011BBB6839783999C9C uuid:6FB8AFE841D9E011BBB6839783999C9C uuid:6DB8AFE841D9E011BBB6839783999C9C uuid:6CB8AFE841D9E011BBB6839783999C9C False PDF/X-3:2002 PDF/X-3:2002 1 False True 55.999941 49.999903 Millimeters Black Standard-Farbfeld … endobj 3686 0 obj >stream 2007-02-16T12:18:18Z 2007-02-16T12:18:18Z Illustrator application/postscript endstream endobj 3687 0 obj > endobj 3688 0 obj >stream application/postscript WBF_SBFI_E_CMYK_pos_hoch Adobe Illustrator CS6 (Macintosh) 2013-03-14T16:21:36+01:00 2013-03-14T16:21:36+01:00 2013-03-14T16:21:36+01:00 xmp.did:0380117407206811822A8A246625707B xmp.iid:0380117407206811822A8A246625707B uuid:CA3160CCD9D4DC11869489A7AC6B4632 proof:pdf xmp.iid:F840227F51DAE1119FAE82E … AE82E4052D00DB 2012-07-30T16:22:10+02:00 Adobe Illustrator CS5 / converted from application/postscript to application/vnd.adobe.illustrator saved xmp.iid:0380117407206811822A8A246625707B 2013-03-14T16:21:36+01:00 Adobe Illustrator CS6 (Macintosh) / 1 False False 7.090489 4.815176 Centimeters Magenta Yellow Black Standard-Farbfeldgruppe 0 Weiß CMYK PROCESS 0.000000 0.000000 0.000000 0.000000 Schwarz CMYK PROCESS 94.529999 82.419998 81.250000 89.449997 Purpurrot CMYK PROCESS 23 … Adobe PDF library 9.90 endstream endobj 3689 0 obj > endobj 3690 0 obj >stream application/postscript Druck 2015-05-11T13:10:42+02:00 2015-05-11T13:10:42+02:00 2015-05-11T13:10:41+02:00 Adobe Illustrator CS5.1 xmp.iid:01801174072068118083B396190F8163 xmp.did:01801174072068118083B396190F8163 uuid:5D20892493BFDB11914A8590D31508C8 proof:pdf uuid:f1
Global Medtech Industry Converges in Düsseldorf as MEDICA 2025 and COMPAMED 2025 Open with Reform Momentum and Future-Health Focus | FairsOnline Skip to main content Home News By Market & Region By Theme Industries Agriculture & Food Production Construction & Infrastructure Manufacturing & Industry Energy & Environment Transportation & Mobility Retail & Consumer Goods Industry Healthcare & Biotech Information & Communication Tech Finance & Investment Professional & Business Services Education, Research & Public Sector Events Search Apply Home Glo
Emerging Medtech Summit 2024 Speakers - Life Science Intelligence Customer Login Contact Home Events Upcoming Events LSI Europe '24 (Sintra, Portugal) LSI USA '25 (Dana Point, CA) Past Events LSI USA '24 (Dana Point, CA) LSI Europe '23 (Barcelona, Spain) LSI USA '23 (Dana Point, CA) LSI Europe '22 (Hertfordshire, UK) LSI USA '22 (Dana Point, CA) LSI USA '21 (Laguna Niguel, CA) LSI USA '20 (Laguna Niguel, CA) Market Intel Medtech Pro Includes all products below Individual Products Market Analysis & Projections (MAP) Market Reports Library Procedure Volumes Database Companies and Deals Database … 2015. While at Gauss, he initiated the development of Triton, a computer vision application for monitoring surgical blood loss, and led the company through De Novo clearance from the U.S. Food and Drug Administration (FDA) in 2014 and early market launch. Under Siddarth’s commercial leadership, Triton was widely adopted by US health systems, surpassing 250,000 surgical procedures annually by 2019 and winning regulatory approvals in the EU and Asia Pacific regions. In 20 … s in the EU and Asia Pacific regions. In 2018, Triton received the Apple Design Award, which recognizes the best in design, innovation, and technology on Apple platforms. In his operating roles, Siddarth raised $60 million in venture capital financing and architected the spinoff of several home diagnostics technologies developed by Gauss in response to the COVID-19 pandemic. From 2011 to 2013, Siddarth served as an Entrepreneur-in-Residence at StartX, Stanford University&rsqu … rsquo;s Startup Accelerator. Prior to founding Gauss, Siddarth held a SIMdesign fellowship in the Department of Surgery at Stanford University and performed research in computer-aided drug discovery at Gilead Sciences. Siddarth received a B.S. in Chemical Engineering from the University of California, Berkeley, and an M.S. in Bioengineering from the UC Berkeley-UCSF Joint Graduate Group in Bioengineering. He holds over 50 issued or pending patents in the fields of surgery, di … ble for TVM Capital Life Science’s overall investment strategy and global fund operations. Dr. Marengère joined TVM in 2012 and has 23 years of venture capital experience. He was a key driver of the implementation of the TVM LSI I investment strategy which resulted in a number of investments. He is a Director on the Boards of Emovi I
%PDF-1.7 %���� 1 0 obj >/Metadata 404 0 R/ViewerPreferences 405 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/MediaBox[ 0 0 595.32 841.92] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x�� ks��g� ����3L��h2��}wɵM'���I>�(Z֜%*���뻻x��H�q�f�'X��ž����f����m��7���m�?���˻r������!�/V�vQ�.?�>m��"�������m���Y�B�/Ib ��N5�"Hg�6���� V�g7w�g��y�9 Upw~��a��8d�RA ��n `�~��y3szK�۷�g?N������������:?�� .{�|Sn�����r��m�,�Z�V\�PB�XЮi�v���{|a���i�j��h�j"�_�������ޢ����W���>)�$����B#��.��G���m��QW��x�?,�y�o���EE!�
Good things come in threes News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capital Report Download the latest reports SV … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout January 12, 2024 Good things come in threes Dear reader This week one piece of news clearly received the most attention from us: the takeover of Sevensense by ABB . The Swiss technology group is very familiar with the ETH Zurich spin-off: they have been working together since 2021. ABB is now rapidly rolling out autonomous mobile robots with Sevensense’s vision navigati … side. Kickfund has become operational, with CHF 70 million raised for the first fund – CHF 10 million more than originally targeted. The fund is still open to qualified investors. Kickfund invests exclusively in start-ups that have been through all three stages of Venture Kick. ETH Zurich provided the third positive surprise, with 43 spin-offs created in 2023 . This is well above the level of the previous 10 years. These three news items illustrate the dynamics of the ecosyst … roaching. Registration is open for Venture Leaders Technology until Monday. The application deadline for Startfeld Diamant is 21 January, the SEF Award on 26 January and the Future of Health Grant on 31 January. Four start-ups have already been awarded the Innosuisse certificate ; we present the companies in our article. We will present the new S
%PDF-1.7 %���� 1 0 obj > endobj 2 0 obj > endobj 3 0 obj > endobj 4 0 obj > endobj 5 0 obj >/DA(/ 0 Tf )/F 134/FT/Sig/Lock 8 0 R /P 4 0 R /Rect[ 0 0 0 0]/Subtype/Widget/T /TU /Type/Annot/V 9 0 R >> endobj 6 0 obj >>>/Subtype/Form/Type/XObject>>stream x��R��3Rp��n� endstream endobj 7 0 obj >/Subtype/Form/Type/XObject>>stream x����Pp�u�R(TPTp�*T# endstream endobj 8 0 obj > endobj 9 0 obj /Filter/Adobe.PPKMS/M(D:20230602095858-07'00')/Prop_Build >/Filter >/PubSec >>>/Reason(Digitally verifiable PDF exported from www.docusign.com)/Reference[ >/Type/SigRef>>]/SubFilter/adbe.pkcs7.detached/Ty … 0 R ] endobj 26 0 obj > endobj 27 0 obj >stream PDFKit.NET 23.1.203.40784 DMV9 application/pdf [WIP] voltWall Form C/A 3.docx 2023-06-01T15:31:50-05:00 uuid:9df050b6-a81a-3a44-8ff2-c618b8079402 uuid:87d0de9e-2906-b34e-b94f-44a72af1926b 1.7 2023-06-02T09:58:59-07:00 2023-06-02T09:58:59-07:00 <TrackingInformation><EnvelopeID>9143cb54-94e9-42ed-a2a3-8c208c2c88d3</EnvelopeID><DocumentID>1</DocumentID></TrackingInformation> <?xml version="1.
S²CUBE丨瑞士医疗科技公司Bottneuro研发个性化非侵入式神经刺激器，实现阿尔兹海默症精准治疗医药新闻-ByDrug-一站式医药资源共享中心-医药魔方 首页 行业报告 医药新闻 医药日历 数据查询 医药政策 博客中心 全球资源链接 资本透视 全球医疗健康投融资数据平台 专利布局 全面易用的医药专利检索平台 专业的生物序列检索平台 竞争监测 更快、更全、更准的全球新药情报 全球一站式药品信息查询 临床试验 荟萃医学证据，洞悉全球临床试验格局 市场销售 中国核心医院药品销售数据库 中国核心医院渠道竞品监测平台 医院患者潜力数据库 中国实体零售药品销售数据库 中国实体零售渠道竞品监测平台 医疗器械 一站式全球器械数据情报分析平台 一站式医疗器械信息查询 定制服务 数字化解决方案 助力企业情报数智化体系搭建 登录 医药魔方ByDrug ByDrug首页 > 医药新闻 > 新闻详情 > S²CUBE丨瑞士医疗科技公司Bottneuro研发个性化非侵入式神经刺激器，实现阿尔兹海默症精准治疗 2025-08-27 15:26 查看原文 收藏 自2011年以来，瑞士连续13年全球创新指数排名第一，是全球重要的创新策源地，也是中国首个创新战略伙伴关系国，在生命健康、先进制造、低碳科技等领域与中国具有极佳互补性。 BioBAY与Insight Tech 共建的S²CUBE（中
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
🚀 Meet the Top 10 Wearable... - Innovation World Cup Series Facebook Log In Innovation World Cup Series's Post Innovation World Cup Series April 23, 2025 · Shared with Public Meet the Top 10 Wearable Tech Innovators! The future of wearable technology is here! We’re thrilled to announce the 10 finalists of the Wearable Technologies Innovation World Cup®, shaping the next big breakthroughs in IoT, Wearable Tech, and DeepTech. Congratulations to: AUXSYS Bottneuro AG Cynteract EVERSION Technologies Exoheal INCLUSYS MindSpeller BCI BV MotionMiners GmbH Syntropic YU.SH These finalists will be
Positrigo - Imaging Everyone Product Applications Dementia Neuro-Oncology Epilepsy Movement Disorders Research Whitepapers/Webinars Services Clinical Technical About Team Careers Board of Directors Advisory Board Partners News Blog Meet us here Contact EN DE EN (USA) Product Applications Dementia Neuro-Oncology Epilepsy Movement Disorders Research Whitepapers/Webinars Services Clinical Technical About Team Careers Board of Directors Advisory Board Partners News Blog Meet us here Contact EN DE EN (USA) Launch of BrainPET Accelerator program in the U.S. Imaging Everyone NeuroLF is an ultra-compa … PET technology gains momentum News Positrigo Reaches Final of the Swiss Medtech Award 2026 March 12, 2026 Positrigo among top 3 of the Swiss Medtech Award 2026 News Launch of the BrainPET Accelerator program in the U.S. February 19, 2026 Positrigo launches the BrainPET Accelerator Program in the US News Positrigo joins the ACCESS-AD Initiative January 13, 2026 ACCESS-AD launches to advance Alzheimer’s disease diagnosis and treatment across Europe News First NeuroLF® System So … to become Positrigo’s distributor in France News Positrigo wins iF Design Award 2025 March 3, 2025 Positrigo wins iF DESIGN AWARD 2025 – an outstanding success in international design News 2024 – A Year of Milestones December 30, 2024 Positrigo looks back on a successful year with numerous achieved milestones News Positrigo Secures CE Mark in Europe for its Pioneering Dedicated Brain PET System October 2, 2024 Positrigo secures CE Mark in Europe for NeuroLF System … eliminary performance data of NeuroLF News Positrigo receives Swiss Accelerator grant May 3, 2023 Positrigo receives Swiss Accelerator grant from Innosuisse News 2022 Review December 29, 2022 Positrigo reflects on a successful Year. News Proof-of-Concept Publication in Journal of Imaging December 21, 2022 Positrigo team co-authors proof-of-concept study News Positrigo closes successfully Series B Funding Round. October 24, 2022 Positrigo receives CHF 5.5 million in Series B f … trigo is among the top 50 companies competing for the W.A. de Vigier Foundation Award 2022. News Positrigo selected for IMD Startup Competition 2021/2022 December 17, 2021 Positrigo is among 37 companies which have been selected to participate in the 2021/2022 IMD Startup Competition News Positrigo and Bottneuro sign collaboration agreement Novem
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
- YouTube Info Presse Urheberrecht Kontakt Creator Werben Entwickler Impressum Verträge hier kündigen Nutzungsbedingungen Datenschutz Richtlinien & Sicherheit Wie funktioniert YouTube? Neue Funktionen testen © 2026 Google LLC
#study #safety #comfort #healthcare #neuroscience #neurostimulation #health #medtech #medicine #therapy #clinicalstudy #study #hospital #clinicaltrial #neuromodulation #medicaldevices #alzheimers… | Bottneuro AG | 18 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your … asel together with Bottneuro as sponsor. - MINDSTIM paves the path for clinical application of the Miamind® Neurostimulator for home-based, repetitive neuromodulation. Over the last years, we’ve developed the Miamind® Neurostimulator for precise, non-invasive neuromodulation using mild alternating currents to entrain neural activity in targeted brain regions. These days we’ve received all necessary approvals to begin our initial clinical trial with the personalized Miamind® N
--> University in the News | University of Basel Jump to: Content Mainnavigation Search Footer Introduction Links --> Introduction Links Navigation --> Prospective Students Further information Students Further information PhD Candidates Further information Donors & Alumni Further information Lecturers Further information Locationfinder --> Locationfinder Navigation --> x + - Navigationarea University of Basel --> Metanavigation --> Deutsch Organizational units Documents Information for... Locations of the University of Basel Search open Persons open Searchbar --> Find content in corporate webs … Service Ukraine UNI NOVA Social Media Studies Before My Studies Degree Programs Application & Admission Dates Informations, Events & Get a Taste Student Advice Center Academic Advice Five reasons for studying in Basel In My Studies Course Directory Course Registration Semester Registration Dates Documents & Verification Welcome to the University of Basel Mobility Campus Credits Course Auditors Student Life Campus Stories Advice & Support Academic Advice Studen … ctory Social Media Guidelines Studies Studies Before My Studies Degree Programs Application & Admission Application & Admission Application Admission Admission Bachelor's studies Bachelor's studies Master’s studies Master’s studies Doctoral studies Language Skills Matriculation Visa / Residence Permit Tuition Fees Information for refugees Dates Dates Semester Dates 2025–2029 No Lectures Deadlines Deadlines Application deadlines Deadlines Semester Registratio … g Tips and Tricks for Job Applications and Interviews Literature 15 career tips Application Training Application Training Tips and Tricks for Job Applications and Interviews Events Events CSC-Calendar Long Nights of Careers 2024 Programme of the LNoC 2024 Job Board Employers from A to Z Employers from A to Z Services and Prices Form for employer portrait Team Social Services & Health Care Social Services & Health Care Disability & Illness Disability & Illness … assment Sexual Harassment Awareness Day 2026 Social Services Student Solidarity Fund Military & Civilian Service Coordination Office for Refugees Inclusive University Support Services Guide Learning & Teaching AI in learning and teaching Digital learning Digital learning UPGRADE your digital skills Language Center Learning Spaces Learning
Dr. Hopf, CSO of Bottneuro, develops Miamind neurostimulator for Alzheimer's | Sachs Associates posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue … al in Basel, he co-founded Bottneuro to bring his academic findings to clinical application. Since incorporation in 2021, Bottneuro has developed the custom-made Miamind neurostimulator for personalized, transcranial electrical stimulation at home. In 2024, Dr. Hopf led the first clinical trial of Bottneuro investigating the safety and feasibility of the Miamind neurostimulator. Since then, the Miamind neurostimulator has been registered as a custom-made medical device and is … on the global stage—advancing to the semi-finals of the Alzheimer’s Insights AI Prize organized by the Alzheimer's Disease Data Initiative By building on the foundation of MINT-AD, our deep-learning platform that unites complex clinical and biological information, we’re pushing the boundaries of what’s possible in Alzheimer’s drug discovery. For more information, please visit: https://bit.ly/47D7n9C #AlzheimersResearch #AIinHealthcare #HealthcareInnovation #Neuroscience #IGCP … linical diagnostics and research laboratories. ✅ Detailed segmentation by type, application, and global region. https://lnkd.in/dR67sege ✅ Key Players: DIXI medical FHC Group Intamed Ad-Tech Medical Instrument Corporation GVB-geliMED GmbH HKHS Integra LifeSciences Cadwell PMT Corporation Alliance Biomedica Pvt Ltd #DepthElectrodes #NeuroDiagnostics #MedicalDevices #HealthcareInnovation #MarketResearch #RegalIntelligence #Neuroscience #HealthcareTech #MedicalTechnology View C2
Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro | Bottneuro Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro | Bottneuro Who we are Operational Team Advisors Board Partners What we do Contact Us News Dr Antonella Santuccione Chadha joins the Board of Directors at Bottneuro Posted on 02 June, 2025 It is an honor to welcome Dr. Antonella Santuccione Chadha to the Board of Directors at Bottneuro AG - bringing her extensive expertise to build our clinical strategy, supporting the company’s mission to bring precision neuromodulation solutions to Al … rs, including Woman of the Year in Switzerland (2019), the World Sustainability Award, and the Veuve Clicquot Bold Woman Award (2022) and and most recently, recognition for her contributions to Swiss reforms through the Katherinenturm Project (2024). test Contact [email protected] +41 61 515 00 43 Follow us: Site Map Who we are What we do Contact Us News Headquarters Bottneuro AG Lichtstrasse 35 4056 Basel, Switzerland Bottneuro Inc. 2261 Market Street #5107 San Francis
Bottneuro AG of Basel at MEDICA 2025 in Düsseldorf Skip to main content --> Main navigation Close Back --> --> --> Home Help & Arrival Contact International Representatives Arrival Hotel & CityInfos FAQ Exhibit Trade Fair Participation Online registration Become an exhibitor Stand Cost Calculator Focus topics Trade fair preparations MEDICA HOSPITAL OF THE FUTURE Information Contact persons Download center At a glance Service ABC Hotel & CityInfos Stand constructor portal Traffic regulations Services Fair Match Online-Order-System (OOS) Exhibitor Profile Exhibitor dashboard Scan2Lead Logos & ba … Press Accreditation Press contact Press releases Exhibit Exhibit Exhibit Online Application Online Order System Marketing Services Exhibitor contact Dashboard Parallel event Parallel event Parallel event COMPAMED About MEDICA About MEDICA About MEDICA Product Categories At a glance Newsletter Spheres of MEDICA-Magazine Contact & Support Write to us Hotline +49 211 / 4560-01 FAQs Digital Services Act (DSA) Legal Imprint Privacy Policy Accessibility Compliance Cookie Settings F
%PDF-1.7 %���� 1 0 obj >/Metadata 68336 0 R/ViewerPreferences 68337 0 R>> endobj 2 0 obj > endobj 3 0 obj >/ExtGState >/XObject >/ProcSet[/PDF/Text/ImageB/ImageC/ImageI] >>/Annots[ 20 0 R] /MediaBox[ 0 0 595.44 841.68] /Contents 4 0 R/Group >/Tabs/S/StructParents 0>> endobj 4 0 obj > stream x��]�r���J��#�Q �dU*U��Ƒ��n�J���� Q�ij3ʈ�f /� ? Q[y��Fws���o�� ��,��T������ 'T�C���B�{�#�f� �P����3����� �����/�ܶ|�� �O� �������{lp���9�{7�e��8w·���e�J�I�@�)� e �eF܀;��5 n���� aH�_�6A�U���FJ���_�Z��%[.H��(�.�FWI���Rb�Z)1�6R�`� [qn������+�V t% t�����VEh�Io} ���c��z��,}��-�S,i�I��H�
Instagram See everyday moments from your close friends . Log into Instagram Mobile number, username or email Password Log in Forgot password? Log in with Facebook Create new account Meta About Blog Jobs Help API Privacy Terms Locations Popular Instagram Lite Meta AI Threads Contact Uploading & Non-Users Meta Verified English Down chevron icon Afrikaans العربية Čeština Dansk Deutsch Ελληνικά English English (UK) Español (España) Español فارسی Suomi Français עברית Bahasa Indonesia Italiano 日本語 한국어 Bahasa Melayu Norsk Nederlands Polski Português (Brasil) Português (Portugal) Русский Svenska ภ
Samsung Bottneuro | Kunde & Co Services Work About Industries Insights Careers Get in touch Services Brand Strategy & Communication Marketing Strategy & Activation Digital Brand Experiences Product & Portfolio Marketing Sustainability & ESG Market Analysis & Insights Mergers & Acquisitions (M&A) Employer & Talent Engagement See all our services Work About Industries Agriculture Building & Construction Consumer & Lifestyle Energy Finance Food & Beverage Healthcare Industrial Maritime & Logistics Public sector Retail Technology See
Bottneuro secures $4.3M to develop its non-invasive Alzheimer’s treatment | BioWorld BioWorld. Link to homepage. BioWorld BioWorld Science BioWorld Asia Data Snapshots Biopharma Medical technology Infographics: Dynamic digital data analysis Index insights NME Digest Special reports Infographics: Dynamic digital data analysis BCI Ebola outbreak Hantavirus Trump administration impacts Med-tech outlook 2026 Under threat: mRNA vaccine research BioWorld at 35 Biopharma M&A scorecard Bioworld 2025 review BioWorld MedTech 2025 review BioWorld Science 2025 review Women's health China's GLP
Biosensors for Medical Wearables : Pharma : North America About Us Privacy Policy Conduct Speak Sponsor Attend Sign up / Login Sign out +44 (0)20 7827 6000 [email protected] Basket Total: £0.00 Toggle navigation Toggle menu --> Toggle navigation Home Defence & Security All Events Loitering Munitions Space & Satellites C-UAS Pharmaceuticals All Events Pre-Filled Syringes Utilites Aviation Digital & Print Media About Us Privacy Policy Conduct Speak Sponsor Attend Help Home Defence & Security All Events Loitering Munitions Space & Satellites C-UAS Pharmaceuticals … e MIT Computational Cardiovascular Research Group. She received the MIT Legatum Fellowship and the MIT Graduate Women of Excellence Award. She has also been recognized as a 2018 Medtech Boston 40 under 40 Healthcare Innovator, and in the top 100 Female Founders across the U.S. by Inc Magazine. Prior to MIT she worked in the semiconductor industry at companies such as HP and Teradyne and co-founded MenTe en Acción (Mujeres en Tecnología) where she currently serve … national awards and high calibre endorsements for its innovations, including an award from the XPrize Foundation. Biovotion was acquired by Biofourmis in 2019. Today he is working at the interface of secured medical technology, physiological monitoring and data science, towards a more holistic view of health. Branislav Vajdic Founder and CEO, HeartBeam Branislav Vajdic, PhD, Founder and CEO of HeartBeam, Inc, combines over 30 years of experience in technology development and … m at Riverbed, she spearheaded the go-to-market strategy of the company’s application performance platform. An active leader in the startup community with an MBA from Imperial College London and MSc in Health Economics from London School of Economics, Catherine provides guidance and mentorship to other entrepreneurs as an Executive Mentor for Santa Cruz Accelerates and a Program Lead for the Startup Leadership Program. In her downtime, you’ll likely find Catherine … ment and strategic planning. Girish holds an MBA from Boston University. Grant Weller SVP Data Science, BioIntelliSense, Inc. Grant Weller is Vice President, Data Science at BioIntelliSense, Inc., a Denver-based continuous health monitoring and clinical intelligence company. Grant is responsible for the development and implementation of cl
Bottneuro AG | Global Innovation Summit 2026 Global Innovation Summit 2026 6 May 2026 | Basel, Switzerland Home Programme Matchmaking Help Log in Register Log in Register Log in Register B Bottneuro AG SME bottneuro.ch/en Basel, Switzerland 20 profile visits About Representatives About Bottneuro strives to set new standards in personalized neuromodulation - achieving better results and improving quality of life. Find out more! What is your business/industry sector? Biotech, Pharma and Cosmetics Healthcare Nano and Microtechnologies Representatives T T Tino Töpper Board member / Founder Bottneu
Bekim Osmani - Executive Bio, Work History, and Contacts - Equilar ExecAtlas Request a Demo Engage Executives. Unlock Deals. ExecAtlas delivers real-time insight into who-knows-who, paving the way for warm introductions that create opportunities. Search for an Executive Trusted by Industry Leaders Trusted by Industry Leaders Featured Profile Bekim Osmani Chairman at Bottneuro Bekim Osmani 's Executive Work History Current Chairman , Chairman Equilar on 03/19/2026 Bottneuro Past To view Bekim Osmani's complete executive work history, sign up now Bekim Osmani 's Connections (14) Lucie Bréchet Ad
Startups developing augmented reality based safety systems for motorcycles, next-gen probiotics, neuromodulation therapies, automated reporting in medicine, and energy storage systems each win CHF 10,000 Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY --> Login Username Password Forgot password / Create a new password EN DE FR Login Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY EN DE FR Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY Login Back to overview Startups developing augmented reality based safety … working together on voltWALL’s core product: An advanced, user friendly, multi-application energy storage module called ‘xBlade’, that offers solutions with far greater flexibility in either stationary or mobile energy storage applications. The innovation provides clean, affordable, transportable and secure energy. The xBlade is based on lithium cells providing modularity for each solution that voltWALL offers to the market. Each module is individually monitored so that any
#neurosurgeons #researchers #innovators #neuroscience #medtech #innovation #neurostimulation | Bottneuro AG LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, yo
Science-Switzerland - News Gateway Abstract A Therapeutic Helmet Promises Advances in the Treatment of Alzheimer's (University of Basel, April 11, 2024) Bottneuro AG co-founders Bekim Osmani, PhD and Prof. Dr. Raphael Guzman, are developing an innovaitve neurostimulator named Miamind, in collaboration with the University of Basel. Built with a focus on treating degenerative diseases like Alzheimer's and Parkinson's, Miamind promises targeted brain electrostimulation at home. The breakthrough of this device lies in employing targeted brain electrostimulation to tackle degenerative conditions li
%PDF-1.7 %���� 967 0 obj >stream h�ԛ[� � F�J?&O�u#Y@`�� ��e � ��D,��5����=��ڑc�E F^T�3��n�,v�����K�c�� Y�h^�2�-e�K���X����Ֆ֊,����ҖZW���TmK_���+�]aK/u���W����U�ް ��,"뢽�W��m�+U�OƢ���W�/]�ܠ�yeF�� �X���ꍵxż���J��nԪU�/�ZT�Wf�d�.���F �y�B5_ 1����[V�G�-�/��[�>'���5�l��1f�ĘM�Yc̾�Ƙ��l1�.�ǘ}�g�1Ϻ�c�vSb��-��d�e[��[6�6ny�t�[�1�9���> ]}S�������k�Z�)��{�6���=j���C!^���zMjh-j3�ч�Ԣ%���Z�a>-�����xǮpT����>J��>�6 E)�X����x e��U C���x��R��Q���G�Pk��h�>f̷z u�>��QK�Q-jчϪ�}4裕�E �������@��֣}4�n�Ң�m]Z���K�>�ui�Ƕ.=����g_ڶ.�4^�uq��%�uqw,�����۽���V�Fm���pW��f��3���$vD �:����n�1���1�� … 0 0 0 0 0 0 0 0 507] endobj 958 0 obj >stream Microsoft® Word für Microsoft 365 application/pdf White paper Miamind Brochure Draft I Microsoft® Word für Microsoft 365 2024-02-29T17:30:43+01:00 2024-05-02T17:06:09+02:00 2024-05-02T17:06:09+02:00 uuid:2E143F88-2F40-480B-9950-E1696D642C2D uuid:f5ce3609-95d3-4431-8e66-21bca69645fa endstream endobj 959 0 obj > endobj 963 0 obj >/Font >>>/Fields[]>> endobj 964 0 obj >stream H��W[o�F~���B,�1��( $�7M��&��>�}Pm�Q!K�,�h�~gfH�6�i�� … 3� ����g�����s�qI!�IHE,�c��,$E�"�b >stream Microsoft® Word für Microsoft 365 application/pdf Miamind Whitepaper Microsoft® Word für Microsoft 365 2024-02-29T17:30:43+01:00 2024-05-02T17:11:33+02:00 2024-05-02T17:11:33+02:00 uuid:2E143F88-2F40-480B-9950-E1696D642C2D uuid:3c037592-5957-46e8-9fa4-e34124906d97 endstream endobj 976 0 obj > endobj 977 0 obj >/Filter/FlateDecode/ID[ ]/Index[4 1 147 1 151 1 663 1 958 1 960 1 976 2]/Info 976 0 R/Length 45/Prev 1511453/Root 1 0 R/Si
Bottneuro secures CHF 4 million to develop its non-invasive Alzheimer's treatment Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY --> Login Username Password Forgot password / Create a new password EN DE FR Login Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY EN DE FR Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY Login Back to overview Bottneuro secures CHF 4 million to develop its non-invasive Alzheimer's treatment 15.12.2022 The startup, which is developing a non-invasive, home-based treatment for early
#phd #career #universityofbasel #science #research #neuroscience #peripheralnerveinjuries #neuromodulation #bottneuro #startup | Alois C. Hopf, PhD | 28 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Joi
CHF 150,000 to advance personalized therapies for Alzheimer’s disease News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Ca … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout CHF 150,000 to advance personalized therapies for Alzheimer’s disease Award Please login or register 20.12.2021 Bottneuro will facilitate the early-stage diagnosis of Alzheimer’s disease (AD) and aims to become a leading provider of personalized digital therapies for AD. The Basel-based start-up will use the CHF 150,000 from Venture Kick to set up PET scan centers and f … A is planned for 2022 and 2023. The Venture Kick funds, complemented by a Kick Fund investment, will lay the foundation for Bottneuro’s ambitious plans and support the preparation of PET scan centers. “Being part of Venture Kick was a game-changer for Bottneuro. It took me away from the scientific world and provided me with the perfect platform to further advance our business model. The timing between the stages was perfectly selected so one could make substantial advances b … ekim Osmani (CEO), Mahyar Joodaki, and Julius Klaas / Venture Kick Never miss a deadline again Start alarms for award deadlines Receive tailor made mails with news about your awards 0 Comments Back to all news Please login or sign up to comment. Commenting guidelines Send Award More news about Bottneuro AG Company profiles on startup.ch Bottneuro
#urbaninnovation #sportforall #communitysports #startuplessons #innovation #marketing #startup | Vincent Borel | 15 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to jo
Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY --> Login Username Password Forgot password / Create a new password EN DE FR Login Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY EN DE FR Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY Login Back to overview Bottneuro wins CHF 150,000 to advance diagnosis and digital therapies for Alzheimer’s disease 17.12.2021 Bottneuro will facilitate the early-stage diagnosis of … A is planned for 2022 and 2023. The Venture Kick funds, complemented by a Kick Fund investment, will lay the foundation for Bottneuro’s ambitious plans and support the preparation of PET scan centers. “Being part of Venture Kick was a game-changer for Bottneuro. It took me away from the scientific world and provided me with the perfect platform to further advance our business model. The timing between the stages was perfectly selected so one could make substantial adva
#lsiusa24 #miamind #personalized #nibs #alzheimer #medtech #bottneuro #neuromodulation #healthtech #neuroscience #entrepreneurship #swissmade #personalizedmedicine #neurodegenerative #tacs #tdcs #eeg | Alois C. Hopf, PhD LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choic
Wearable Technologies | Alois C. Hopf (PhD) Festive Season Savings! Code: WT_HongKong20 We’re gifting you the future. You bring the passion, we’ll give you 20% off your ticket for the WT Conference in Hong Kong . Upgrade your smart mind today. Join Us Now Network News Events Consulting About us EN EN 中文 Contact us Speaker Alois C. Hopf (PhD) CSO & Co-Founder Bottneuro Dr. Hopf is a Swiss neuroscientist, CSO and Co-Founder of Bottneuro. To understand the underlying mechanism of life and how these fundamental mechanisms can be modulated for human benefit, he studied biotechnology at ETH Zuri … al in Basel, he co-founded Bottneuro to bring his academic findings to clinical application. Since incorporation in 2021, Bottneuro has developed the custom-made Miamind neurostimulator for personalized, transcranial electrical stimulation at home. In 2024, Dr. Hopf led the first clinical trial of Bottneuro investigating the safety and feasibility of the Miamind neurostimulator. Since then, the Miamind neurostimulator has been registered as a custom-made medical device and is
Bottneuro Uses Samsung Technology to Provide Bottneuro’s Digital Diagnostic Solutions for the Diagnosis and Treatment Against Alzheimer’s Disease | Samsung Mobile Press Bottneuro Uses Samsung Technology to Provide Bottneuro’s Digital Diagnostic Solutions for the Diagnosis and Treatment Against Alzheimer’s Disease March 08, 2023 With medical technology continuing to evolve and offer the latest solutions and treatment to patients, Samsung Electronics Switzerland has been aiding the advancement by developing its products. Samsung collaborated with Bottneuro AG , a Swiss MedTech startup dedicated … Bottneuro solution. “We were looking for a simple and reliable solution for our application. We found it with the Galaxy Tab S8+ 5G Enterprise Edition and Samsung is giving us great support in the development,” said Julius Klaas, CTO of Bottneuro AG. Seamless Solutions in a Single Galaxy Tablet The Galaxy Tab S8+ 5G Enterprise Edition offers a plethora of features and capabilities. It comes with a high-resolution Super AMOLED display providing brilliant clarity for both patie
--> Innovative treatment helmet promises advances in the treatment of Alzheimer’s | University of Basel Jump to: Content Mainnavigation Search Footer Introduction Links --> Introduction Links Navigation --> Prospective Students Further information Students Further information PhD Candidates Further information Donors & Alumni Further information Lecturers Further information Locationfinder --> Locationfinder Navigation --> x + - Navigationarea University of Basel --> Metanavigation --> Deutsch Organizational units Documents Information for... Locations of the University of Basel Search open Pe … Service Ukraine UNI NOVA Social Media Studies Before My Studies Degree Programs Application & Admission Dates Informations, Events & Get a Taste Student Advice Center Academic Advice Five reasons for studying in Basel In My Studies Course Directory Course Registration Semester Registration Dates Documents & Verification Welcome to the University of Basel Mobility Campus Credits Course Auditors Student Life Campus Stories Advice & Support Academic Advice Studen … fore My Studies Degree Programs ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Application & Admission Application & Admission Application ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Admission Admission ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Bachelor's studies Bachelor's studies ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Master’s studies Master’s studies Doctoral studies Language Skills Matriculation Visa / Residence Permit Tuition Fees Information for refugees ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Dates Dates Semes … emester Dates 2025–2029 No Lectures ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Deadlines Deadlines Application deadlines Deadlines Semester Registration Deadlines Course Registration Informations, Events & Get a Taste Student Advice Center Academic Advice Five reasons for studying in Basel ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ In My Studies Course Directory Course Registration ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Semester Registra … nd Tricks for Job Applications and Interviews Literature 15 career tips ‡ ‡ ‡ ‡ Application Training Application Training Tips and Tricks for Job Applications and Interviews ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Events Events CSC-Calendar Long Nights of Careers 2024 Programme of the LNoC 2024 Job Board ‡ ‡ ‡ ‡ ‡ ‡ ‡ ‡ Employers from A to Z Employers from A to
Companies | Swiss Network for Dementia Research About News Jobs Contact Research Clinic Events Join us Companies Login Companies Industry - a partner to translate research into application Bottneuro Miamind® Neurostimulator - Pioneering Personalised Brain Stimulation Bottneuro has developed the Miamind® Neurostimulator, the world's first fully personalised transcranial electrical stimulation device for home-based neurological treatment. This innovative brain stimulation technology combines MRI-based 3D-printed caps with up to 34 electrodes, enabling precise targeting of specific brain regi … you interested in this cutting-edge treatment option for research and clinical application? Contact us at: [email protected] Carthera Founded in 2010, Carthera ® is headquartered in Lyon. Carthera works closely with renowned academic institutions, like INSERM, Sorbonne University, AP-HP, the interdisciplinary Center for Neuroscience Frankfurt (ICNF), the VHIO Barcelona, Northwestern University and UCSF. Carthera® is a clinical-stage company with its SonoCloud ® implant that … lzheimer’s disease. Neurolite is looking for collaborations to advance clinical application of NIBS-methods in this field. Please contact us at [email protected] for any request or information. Become a Sponsor Support our mission Promote an interdisciplinary community: Engage with experts across various disciplines. Raise awareness: Contribute to greater awareness of neurodegenerative diseases. Position Switzerland as a hub: Help establish Switzerland as a central player in
Miamind News - Research, Developments & Updates Skip to content Home Miamind Science News Contact Home Miamind Science News Contact How to get Miamind? EN DE Get in touch EN DE Home Miamind Science News Contact Home Miamind Science News Contact News Business updated Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND® Explore an Innosuisse-funded clinical trial evaluating MIAMIND® for Alzheimer's disease and potential impact on future treatments. 9 April, 2026 Read more Business updated Miamind at the MEDICA medical trade fair in Düsseldorf Publication Publication in Peer-Reviewed Jo
Bottneuro advances into the clinical phase News Calendar Assets About Us Principal Innosuisse Startupticker Foundation Team Editorial statute Partners & Contributors Supporters Cooperations FAQ Join us Impressum Contact information startupticker.ch Habsburgerstrasse 31 CH-6003 Luzern Tel: +41 41 226 20 80 Fax: +41 41 226 20 89 [email protected] Submit an event Submit special offer Login Register Cancel Forgot password? Login All news Editorial Guest column Startup Media House Get the newsletter Events Trainings Award Deadlines Ecosystem Directory Swiss Venture Capital Report Download the l … ter Register for free to our services and get the newsletter Browse by category Award Background Editorial Expansion Financing Follower Power Guest column Key Partner Launch Partner Post Setback Sponsored Success Support Events Trainings Award deadlines Most viewed events 1 First Swiss Scale-up Report - take part in the survey 2 SHS Webinar "Fuel Your Healthcare Innovation: Unlocking Millions in European Funding" 3 Product Marketing x GTM Meetup in Zurich Submit an … ke-minded people in thestartup community. ecosystem.startupticker.ch Saved news Award Alarms Profile Logout Bottneuro advances into the clinical phase Success Please login or register 08.01.2024 Dedicated to developing a non-invasive Alzheimer’s Disease therapy, Bottneuro has kicked off its MINDSTIM clinical trial to evaluate the safety and comfort of its Miamind Neurostimulator. The study results are expected at the end of March. Based in Basel, Bottneuro has been developing … lts expected at the end of March 2024. MINDSTIM paves the path for the clinical application of the Miamind Neurostimulator for home-based, repetitive neuromodulation. The results will be used to progress the development of neuromodulation therapies for psychiatric and neurological conditions, starting with investigating the efficiency of tACS in Alzheimer’s Disease patients. These trials are performed in accordance with the regulatory authorities to receive clearance and fina … to use the awards follow feature Highlights Bottneuro AG Top 100 Swiss Startup Award 2024 Winner Venture Kick Related News Bottneuro AG 21.07.2025 16:30 Drei Startups verstärken ihre Verwaltungsräte 10.06.2025 17:00 Neue Power für Startup-Geschäftsleitungen 27.11.2024 16:00 Development milestones to propel Medtechs to next step Related tags Read
Dr. Thomas Hefti joins Bottneuro as CEO | Bottneuro AG posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s … iple existing bone cement products, enabling widespread clinical and geographic application. With an aging global population, the need for safer and more effective fracture care is rapidly increasing. 💬 “ Almi Invest has played a crucial role in Inossia AB ’s growth. Beyond financial support, they’ve helped elevate the quality of our work and build the strong shareholder trust we have today.” – Malin Nilsson , CEO, Inossia AB 📩 Interested in learning more about Inossia or o
Bottneuro Revolutionizes Neurocognitive Disorder Management at Novartis Campus | Switzerland Innovation posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Cont … ally targeting Cancer, the Hub will place the Midlands at the forefront for the application of new treatment regimes/new ways of working to improve patient outcomes. It has been a pleasure to act as the lead for this relationship & I look forward to supporting further initiatives such as this. Life Science Hub 158 followers 5mo Edited Introducing the Life Science Hub: Shaping the Future of Healthcare Innovation The Life Science Hub is a newly established team hosted by #U
Salezshark - CRM Software and its marketing automation tools --> -->
%PDF-1.6 %���� 414 0 obj > endobj 434 0 obj >/Filter/FlateDecode/ID[ ]/Index[414 39]/Info 413 0 R/Length 92/Prev 5664012/Root 415 0 R/Size 453/Type/XRef/W[1 2 1]>>stream h�bbd``b`>$��U �YkqYA�*�`�A� �"�A�� �F7D�Ħ�=�) �c� L���@#5�� � o� G endstream endobj startxref 0 %%EOF 452 0 obj >stream h�b```a``*a`e`�ce@Q� st,ZѢ�A,���Gx��.9����S2�T%����} )@ �g��{���q���ئ�L��sĺtU�� ��#:�u�����HJ�&u� M�]y�wٝ� \��3�o�Lg]���2&�yZXAF��P�9ya�Y��b�&�,�]2�m~c��.˃A�R�fw�%p4(��wtt0t�Cy�4/�@q������!�L`�AH�t2�lL�B@� �af�WP�`i��� ��% � � 0?a>z�Y@��! �U�4# � �@� … 12-14T10:57:05+01:00 2024-01-09T16:47:55Z Adobe Acrobat Pro (64-bit) 23.6.20380 application/pdf Miamind Brochure V12 uuid:7863d775-f197-4eba-9225-e0240921abb0 uuid:6626d78d-dc44-4071-bf35-7b3be7ff802a Adobe PDF library 17.00 endstream endobj 163 0 obj >stream h�21�T0P014P05R� �F�@�H���\��F�9�4�(�R Rg�V��@t�~HeA�~@bzj�� \� L�X1D�9�m ��X� R vE^c��J�-���1��0'� C� ��A ����0?�M* endstream endobj 164 0 obj >stream h�D�A �0����܈����"X�M� �˦��`�C�>!�����$ TUv VG … T10:57:05+01:00 2024-05-02T10:48:39+02:00 Adobe Acrobat Pro (64-bit) 23.6.20380 application/pdf Miamind Brochure V12 uuid:7863d775-f197-4eba-9225-e0240921abb0 uuid:a9c42770-77a9-486c-b7b9-b21a7e112eb3 Adobe PDF library 17.00 endstream endobj 416 0 obj >/Font >/ProcSet[/PDF/Text/ImageC]/XObject >>>/Rotate 0/TrimBox[0.0 0.0 595.276 841.89]/Type/Page>> endobj 453 0 obj > endobj 454 0 obj >stream H��WˎdG��W� �;�~Hc b��E#/�h?�� ���xd�n�%X�b�骓�q"��- ᨳ���c�x�y����W�_o���gm … T10:57:05+01:00 2024-05-02T10:54:26+02:00 Adobe Acrobat Pro (64-bit) 23.6.20380 application/pdf Miamind Brochure V12 uuid:7863d775-f197-4eba-9225-e0240921abb0 uuid:83e8cf2b-3078-4842-bc1d-3ccbfd659eb6 Adobe PDF library 17.00 endstream endobj 464 0 obj > endobj 465 0 obj >stream H��WIo ��ϯ�}���@0� �� rH h�I@I�$#���jyK7G�e��z]�֯�yq��Y >,fM��� ����������wx��Y���K~�5�.��װ�b�������|0�q~�ί5[a�~�)�>)����Ť{�#T-���×�a�ф��5VS��7�o��] i�y�����_߿[N�}{�o��C]���1��[�D�\��WojZ … T10:57:05+01:00 2024-05-02T18:04:07+02:00 Adobe Acrobat Pro (64-bit) 23.6.20380 application/pdf Miamind Patient Brochure_EN uuid:7863d775-f197-4eba-9225-e0240921abb0 uuid:4d121dcb-3445-491e-9f5c-dae3786680ea Adobe PDF library 17.00 endstream endobj 479 0 obj > endobj 480 0 obj >/Filter/FlateDecode/ID[ ]/Index[162 1 479 2]/Info 479 0 R/Length 24/P
Biotech VC Funds — Page 9 | Waveup Copilot Assisted fundraising Log in | Sign up Home Guides Assets Investors VC funds Tailored lists Favorites Academy Privacy policy Terms of Use Privacy Policy Help center Return to waveup.com Sector Biotech VC Funds Venture capital funds investing in biotechnology, life sciences, genomics, and biological research startups. Fund profile Geography Check Fund website CV Ventures CV Ventures is a venture capital firm founded in 2013 with a dual base in Hong Kong and Chicago. The firm invests in life science and fintech ventures across Asia and the United States, … startups and more mature businesses across North America and Asia-Pacific. The fund deploys checks of $250,000 to $5 million at seed and Series A stages, led by a two-partner team based in the United States. Portfolio companies include Gini, a fintech platform, and the Model UN Development Organization in the education sector, reflecting the fund's range across technology and mission-driven businesses. With 5 investments across healthtech, fintech, education, and related … — a position that requires genuine operational credibility in both regions. The fund's current status is listed as inactive, though its portfolio represents a selective body of work across the life sciences and fintech sectors that sit at the intersection of the firm's two home markets. Asia-Pacific USA $100K-$500K $500K-$1M +1 Website CyberAgent Capital CyberAgent Capital (CAC) is a prominent venture capital firm specializing in early-stage investments, particularly … startups. Based in Boston, the firm invests globally, targeting companies that apply innovative automation technologies across various industries. Their portfolio includes cutting-edge startups such as Raise Robotics, which develops robots to improve safety and efficiency on construction sites, and Realtime Robotics, which creates processors for rapid, collision-free robot movements in unstructured environments. Cybernetix’s investment strategy focuses on companies in sector … ith deep experience in developer platforms, AI, and enterprise software. With a fund size of $5 million, DarkMode specializes in writing checks between $100,000 and $200,000, focusing on startups in the developer tools, AI/ML, and modern data stack sectors. Notable investments include Drata, Tabnine, Merge, and Bluesky, with the fund targeting bo
Checking your browser - reCAPTCHA Checking your browser before accessing pmc.ncbi.nlm.nih.gov ... Click here if you are not automatically redirected after 5 seconds.
Love it. Now if y'all portfolio companies could agree on a similar logo layout, that would save a lot of time! Just kidding. 😄 Well done and congratulations, everyone! 👏🏼❤️ | Wanja Humanes, CFA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in yo
#brainhealth #neurotech #alzheimers | Bottneuro AG LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agreement , Privacy Policy , a
Zühlke Ventures — Portfolio & Investments | Fundable fundable. DATA PLATFORM Dashboard Companies People Investment Firms Angels & Partners COLLECTIONS Lists Saved Searches Hiring Lists WORKFLOWS Deal Alerts Integrations API + Credits Toggle Sidebar Overview Highlights Investments Team Zühlke Ventures Investments 7 Lead Investments 3 Zühlke Ventures is a corporate venture capital firm that is part of the Zühlke Technology Group AG. It specializes in providing financing and acceleration for technology startup companies at an early stage. The firm leverages its extensive management and te
The team at IMT is proud to be chosen by Bottneuro as a main development partner for their novel neurostimulation device. By using 3D-PET scan data of amyloid beta plaques and tau fibrils distribution in the brain, Bottneuro will apply patient-specific treatment protocols through precise targeting and advanced sensing capabilities. 𝗕𝗲𝗸𝗶𝗺 𝗢𝘀𝗺𝗮𝗻𝗶, 𝗖𝗘𝗢 𝗮𝗻𝗱 𝗖𝗼-𝗙𝗼𝘂𝗻𝗱𝗲𝗿 𝗼𝗳 𝗕𝗼𝘁𝘁𝗻𝗲𝘂𝗿𝗼: “We at Bottneuro aim to become a leading provider of diagnosis and non-invasive neuromodulation therapies for Alzheimer’s patients and have chosen to work with IMT due to its proven … therapy headset, especially the electronics, embedded software, patient-centric application together with the complete technical documentation for certification and registration of the device”. Visit their website: www.bottneuro.ch #makingideaswork #alzheimers #alzheimerscare #alzheimersdisease #medicaldevices #swissmade | IMT
Portfolio companies - HEMEX Skip to content CRO Services Partners Customers About us Certifications News Contact us Portfolio companies Investments Portfolio companies Investments Portfolio companies Investments Annaida Technologies SA MedTech, Women’s Health _ Company profile Annaida is a Swiss Healthtech company, who’s developed and patented a NMR technology, able to provide a fast, non-invasive and quantitative embryo screening, giving patients an improved overall IVF experience. Chief Executive Officer Marco Grisi ARTIDIS AG IVD, Oncology _ Company profile Artidis is a Swiss Healthte … r. Danuta Cichocka CEO, Resistell With its impressive commitment to advance and fund healthcare innovations, its deep understanding of startup needs and its solid expertise in supporting regulatory and clinical operations, HEMEX is an exceptional partner that has been and continues to be instrumental in our journey. Mathieu Horras CEO, ASPIVIX What startups say about up From the start of Resistell, HEMEX supports our company in the clinical operations … r. Danuta Cichocka CEO, Resistell With its impressive commitment to advance and fund healthcare innovations, its deep understanding of startup needs and its solid expertise in supporting regulatory and clinical operations, HEMEX is an exceptional partner that has been and continues to be instrumental in our journey. Mathieu Horras CEO, ASPIVIX Contact us [email protected] Headquarters HEMEX (Switzerland) AG Kasernenstrasse 30 4410 Liestal Switzerland Swit
Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND® | Bottneuro Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND® | Bottneuro Who we are Operational Team Advisors Board Partners What we do Contact Us News Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND® Posted on 08 April, 2026 Bottneuro is pleased to announce that its MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse. Over the next three years, the project “Personalised trans
Developed by Bottneuro AG, a new patient-specific, fully custom-made device allows for at-home treatment of Alzheimer's disease. This is realized through additive manufacturing and a fully digital… | inspire AG LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at
Bottneuro AG - Venture Kick Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY --> Login Username Password Forgot password / Create a new password EN DE FR Login Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY EN DE FR Get the Kick 1234+ KICKS Portfolio Jury Newsroom About us DONATIONS & LEGACY Login Back to overview Bottneuro AG Proximity-based access control for vehicles --> First-in-class precision neuromodulation. Incorporated: 20.01.2021 Headquarter: Basel --> Support: Medtech Medical devices Medtech Neurology Wearable technologies Re
Bottneuro AG: Fostering Innovation at Novartis Campus | Switzerland Innovation Park Basel Area posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to j … e can lead — but only if we act. Three asks will help Austria lead the curve: - Fund translational hubs bundling manufacturing, early trials, and data services to shorten time for first-in-human and proof of concept. - Create formal exchange programs so talent flows between academia, startups, and industry to speed up decision making through building knowledge across the drug discovery and development stakeholders. - Make patient impact the default: require access and evidenc
#brainhealth #neuroscience #alzheimers #womensbrainfoundation | Bottneuro AG | 15 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to Linked … rs, including Woman of the Year in Switzerland (2019), the World Sustainability Award, and the Veuve Clicquot Bold Woman Award (2022) and and most recently, recognition for her contributions to Swiss reforms through the Katherinenturm Project (2024). #brainhealth #neuroscience #alzheimers #womensbrainfoundation 100 15 Comments Like Comment Share Copy LinkedIn Facebook X Keith Mawanda 1y Report this comment A deeply inspiring appointment that signals a bold, evidence-based, &a
Antonella Chadha: Founder @ Wo... - Leading Beyond The Lab - Apple Podcasts Search Home New Top Charts Search 14 February 2025 51 min Antonella Chadha: Founder @ Women's Brain Foundation, TED Speaker, Medical Doctor and Neuroscientist Leading Beyond The Lab Play In this episode, our guest is Dr. Antonella Santuccione Chadha, globally recognised founder of the Women’s Brain Foundation, TED speaker, medical doctor and neuroscientist. Dr. Chadha is also a fractional CMO in Neurology & Medtech, as well as an Advisor to ReconnectLAB, Bottneuro, and EQUAL CARE. We discuss how Antonella paved her
#lifesciences #barcelonalifescience #biotech #innovation | Polar Lab Projects LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or sign in, you agree to LinkedIn’s User Agr … e can lead — but only if we act. Three asks will help Austria lead the curve: - Fund translational hubs bundling manufacturing, early trials, and data services to shorten time for first-in-human and proof of concept. - Create formal exchange programs so talent flows between academia, startups, and industry to speed up decision making through building knowledge across the drug discovery and development stakeholders. - Make patient impact the default: require access and evidenc
Bottneuro AG - Switzerland Innovation Park Basel Area menu search search close back Home Workspaces Community Sites About Us Latest & Events Contact Workspace offerings Coworking spaces Lab spaces Customizable spaces Ready-made office spaces Ready-made workspaces overview Private offices Lab spaces Coworking spaces Customizable spaces Meeting rooms Community Residents Alumni Success stories Main Campus Novartis Campus Jura About us Team Jobs Media corner Latest Events Contact Become A Resident Main Campus Main Campus HQ HORTUS ALL EVENTS THE MAGNET Become A Resident Login You're leaving our we
💜 Today is Purple Day — a moment to raise global awareness for epilepsy. A perfect opportunity to look into some of the fascinating research emerging from our Childhood Epilepsy Center. 🧠 🐟… | Leuven Childhood Epilepsy Center LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update yo … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … ago this week, and one of the highlights is the presentation of the John Dystel Prize for Research in Multiple Sclerosis, awarded jointly by the National MS Society and the American Academy of Neurology. This year's winner of the Dystel Prize is Dr. Ludwig Kappos, a physician-scientist at the University Hospital Basel in Basel, Switzerland, and t
Associations between frailty, biomarkers of cerebral pathology, cognitive and neuropsychiatric symptoms: a memory clinic study | Journal of Frailty and Aging JFA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Joi … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … ago this week, and one of the highlights is the presentation of the John Dystel Prize for Research in Multiple Sclerosis, awarded jointly by the National MS Society and the American Academy of Neurology. This year's winner of the Dystel Prize is Dr. Ludwig Kappos, a physician-scientist at the University Hospital Basel in Basel, Switzerland, and t
#iwctop12healthtechpreneur #healthcareinnovation #innovationworldcupfinalist #medica2024 #pheal #preventivehealth #innovationworldcup #startup #healthcare #rpm #wearables | pheal | 24 comments LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your setti … ontrol of their health with our Smart Patch technology. It’s not just about the award—it's about the connections we’ve made, the feedback we’ve received, and the collective drive to push healthcare boundaries further than ever before. Congrats to the fellow top 12 techpreneurs as well as to Samphire Neuroscience for 1st and MedicubeX Ltd for 2nd place. The high quality of pitches and innovations was truely amazing. It was great to share this experience with all of you: Emilė
Bottneuro: transforming neurocognitive care from Basel’s Novartis Campus - Switzerland Innovation Park Basel Area menu search search close back Home Workspaces Community Sites About Us Latest & Events Contact Workspace offerings Coworking spaces Lab spaces Customizable spaces Ready-made office spaces Ready-made workspaces overview Private offices Lab spaces Coworking spaces Customizable spaces Meeting rooms Community Residents Alumni Success stories Main Campus Novartis Campus Jura About us Team Jobs Media corner Latest Events Contact Become A Resident Main Campus Main Campus HQ HORTUS ALL EVE
BD opens new workspace at HORTUS in Switzerland | Switzerland Innovation Park Basel Area posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
#sachs_htif #neurotech #healthcare #innovation #bci #neuromodulation #basel #htif #sachsforum | Frank Desiere - PhD MBA LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to join or
Bottneuro AG's success at Novartis campus in Basel | Switzerland Innovation Park Basel Area posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicking Continue to
Innosuisse funding for non-pharmacological Alzheimer's treatment | Faculty of Medicine, University of Bern posted on the topic | LinkedIn LinkedIn respects your privacy LinkedIn and 3rd parties use essential and non-essential cookies to provide, secure, analyze and improve our Services, and to show you relevant ads (including professional and job ads ) on and off LinkedIn. Learn more in our Cookie Policy . Select Accept to consent or Reject to decline non-essential cookies for this use. You can update your choices at any time in your settings . Accept Reject Agree & Join LinkedIn By clicki … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim … therapy and her implementation partner Bottneuro AG have received an Innosuisse grant for their project, titled “Personalised transcranial electrical stimulation therapy at home for early-stage Alzheimer's disease”. 💐 Many congratulations! 👏 The project is receiving CHF 900,000 in funding, is scheduled to run for three years and was launched this month. It aims to validate a personalized, home-based electrical stimulation therapy as a symptomatic treatment for early Alzheim
Positrigo - Positrigo and Bottneuro sign collaboration agreement Product Applications Dementia Neuro-Oncology Epilepsy Movement Disorders Research Whitepapers/Webinars Services Clinical Technical About Team Careers Board of Directors Advisory Board Partners News Blog Meet us here Contact EN DE EN (USA) Product Applications Dementia Neuro-Oncology Epilepsy Movement Disorders Research Whitepapers/Webinars Services Clinical Technical About Team Careers Board of Directors Advisory Board Partners News Blog Meet us here Contact EN DE EN (USA) Positrigo and Bottneuro sign collaboration agreement Nove
News | Latest News about Bottneuro News | Latest News about Bottneuro Who we are Operational Team Advisors Board Partners What we do Contact Us News Latest news Business Update Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND® The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse. 08 April, 2026 Read more Events & Conferences Miamind at the MEDICA medical trade fair in Düsseldorf Featured Where the future works: the Novartis Campus All Cat … Expo symposium on Wednesday, September 13, 2023, everything will revolve around application examples from manufacturing. Business Update | Fri 09, 2023 Miamind® Neurostimulator Achieves Official Certification from DEKRA Bottneuro has received official confirmation from DEKRA that the Miamind® Neurostimulator has successfully passed all relevant external device tests. Bottneuro Team | Sat 07, 2023 Prof. Christoph Michel joined as an Advisor As EEG measurements play a crucial r
Bottneuro | Precision Medicine for Brain Health Bottneuro | Precision Medicine for Brain Health Who we are Operational Team Advisors Board Partners What we do Contact Us News Precision medicine for brain health Discover Miamind Innosuisse-Funded Alzheimer’s Clinical Trial with MIAMIND® The MIAMIND® electrical neurostimulator will be evaluated in a randomized, sham-controlled clinical trial in patients with early-stage Alzheimer’s disease (AD), supported by funding from Innosuisse. Miamind at the MEDICA medical trade fair in Düsseldorf Miamind was there! At the world’s largest medical technolog